CRIS Current Research Information System

COLANGELI, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.883
AS - Asia 1.110
EU - Europa 1.104
AF - Africa 107
SA - Sud America 68
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 4.276
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.864
SG - Singapore 369
CN - Cina 308
GB - Regno Unito 238
SE - Svezia 216
VN - Vietnam 193
IT - Italia 162
DE - Germania 143
HK - Hong Kong 121
IN - India 66
RU - Federazione Russa 64
FR - Francia 58
IE - Irlanda 54
BR - Brasile 52
TG - Togo 51
UA - Ucraina 44
NL - Olanda 26
BG - Bulgaria 24
JO - Giordania 24
ZA - Sudafrica 23
EE - Estonia 21
FI - Finlandia 21
CI - Costa d'Avorio 18
MX - Messico 8
NG - Nigeria 8
CA - Canada 7
ID - Indonesia 7
JP - Giappone 7
BE - Belgio 6
CH - Svizzera 6
PL - Polonia 6
AT - Austria 5
EC - Ecuador 5
AR - Argentina 4
BD - Bangladesh 4
SC - Seychelles 4
CO - Colombia 3
EU - Europa 3
KR - Corea 3
CL - Cile 2
ES - Italia 2
LT - Lituania 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
GR - Grecia 1
GT - Guatemala 1
IL - Israele 1
KE - Kenya 1
LB - Libano 1
MS - Montserrat 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
VE - Venezuela 1
ZM - Zambia 1
Totale 4.276
Salva come PNG Salva come JPEG
Città #
Ashburn 254
Singapore 244
Southend 210
Fairfield 183
Chandler 162
Santa Clara 125
Hong Kong 120
Woodbridge 104
Seattle 100
Houston 88
Wilmington 69
Princeton 63
Cambridge 58
Dublin 54
Beijing 52
Dong Ket 52
Bologna 51
Lomé 51
Ann Arbor 47
Boardman 42
Nanjing 29
Florence 26
Hanoi 26
Los Angeles 26
Westminster 26
Ho Chi Minh City 25
Amman 24
Berlin 24
Sofia 24
Padova 20
Abidjan 18
Jacksonville 18
Jinan 14
New York 14
Saint Petersburg 14
Hebei 13
Redondo Beach 13
San Diego 13
Turin 13
Buffalo 12
Dearborn 12
Hefei 12
Redmond 12
Milan 10
Turku 10
Changsha 9
Chicago 9
Dallas 9
Des Moines 9
Nuremberg 9
Olalla 9
Shenyang 9
Abeokuta 8
Frankfurt am Main 8
Guangzhou 8
Helsinki 8
Rome 8
Zhengzhou 8
Nanchang 7
Ningbo 7
Tianjin 7
Tokyo 7
Bremen 6
Brooklyn 6
Brussels 6
Phoenix 6
Bern 5
Bühl 5
Düsseldorf 5
Falls Church 5
Jiaxing 5
Lanzhou 5
Munich 5
Shanghai 5
Shenzhen 5
Shijiazhuang 5
Taizhou 5
Yubileyny 5
Hangzhou 4
São Paulo 4
The Dalles 4
Warsaw 4
Bogotá 3
Elk Grove Village 3
Goiânia 3
Montreal 3
Mountain View 3
Mülheim 3
Ninh Bình 3
Norwalk 3
Salt Lake City 3
Seoul 3
Toronto 3
Wuhan 3
Xi'an 3
Appleton 2
Atlanta 2
Bexley 2
Caxias do Sul 2
Chennai 2
Totale 2.865
Salva come PNG Salva come JPEG
Nome #
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 177
Calcaneal quantitative ultrasound (QUS) and dual X-ray absorptiometry (DXA) bone analysis in adult HIV-positive patients. 171
A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues 169
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 163
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 159
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 158
Skeletal muscle toxicity in HIV-1-infected patients treated with a raltegravir-containing antiretroviral therapy: a cohort study. 156
Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. 151
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 149
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 148
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. 146
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 146
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 141
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 141
Abacavir-lamivudina versus tenofovir-emtricitabina più atazanavir-ritonavir nella semplificazione dell'HAART per dislipidemia 141
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitors: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/mmc) 140
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 140
Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS 140
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 139
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 135
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 130
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 126
Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy 125
Raltegravir use prospectically assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile 122
null 113
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 111
Integration among hospital pharmacists and infectious diseases physicians in the outpatient management of HIV infection 107
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up 103
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 97
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 90
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 78
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 67
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 48
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 33
Totale 4.360
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.769
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.769
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021221 0 0 0 0 0 15 5 10 36 20 15 120
2021/2022649 54 27 35 79 66 26 12 29 21 114 108 78
2022/2023694 51 102 23 94 44 44 11 62 148 19 67 29
2023/2024211 14 31 9 33 10 52 8 21 7 11 9 6
2024/2025724 33 70 57 69 173 35 29 17 5 45 20 171
2025/2026763 166 108 118 108 190 73 0 0 0 0 0 0
Totale 4.360